Rational Discovery.
Real Therapeutics.
1cBio is an emerging biotech company based in the San Francisco Bay Area developing precision medicines for significant unmet needs.
Our Programs
OC-1/ALE1
for hypophosphatasia
ALE1 (OC-1) is a potential first oral therapy for hypophosphatasia.
OC-3 for ovarian, prostate and breast cancers
OC-3 is a potential best-in-class, next generation PARP1-selective inhibitor that aims to maximize efficacy and avoid significant hematologic toxicities exhibited by non-selective PARP inhibitors.
We focus on defined mechanisms of action which are validated in clinical practice, clinical trials, or preclinical models. Typically, our programs are geared to treat the disease and preemptively counter mechanisms for acquired or intrinsic resistance.
We combine our core expertise in medicinal chemistry and translational sciences with thought partners in clinical and basic sciences to guide our innovation. Together with our network of research and development partners, our discovery platform is rapidly scalable and easily tailored to suit our current and future needs.
Our most advanced programs are a potential first oral therapy for hypophosphatasia (HPP) and a potential best-in-class, selective PARP1 inhibitor. Through a partnership with Alesta Therapeutics, our HPP program entered clinical development in 2025 and is currently being evaluated in an ongoing Phase 1/2a clinical trial assessing safety, tolerability and pharmacokinetics/pharmacodynamics. PARP1 is the first program from our emerging portfolio of DDR-related programs for ovarian, prostate and breast cancers. Other early-stage programs are focused on lung cancer and myeloproliferative diseases.
